New cancer vaccine raises hopes

Surgery.

Surgery. mbl.is/Eggert Jóhannesson

A cancer vaccine developed using genetic sequencing of a patient's cancer cells after surgical removal of a tumor is raising hopes that it may be possible to significantly reduce the risk of cancer recurrence in patients who have had high-risk melanoma removed. The treatment could substantially improve their chances of survival.

A study highlighting these findings was presented at a major conference of the European Society for Medical Oncology in Madrid last month.

Helgi Hafsteinn Helgason, a specialist in internal medicine, oncology and clinical pharmacology at the South Iceland Healthcare Institution in Selfoss, attended the conference.

He explains that the process involves sequencing large numbers of DNA and RNA fragments to identify mutations and other abnormalities in the cancer cells. A personalized vaccine is then produced containing an mRNA sequence encoding up to 34 proteins characteristic of the individual patient's cancer.

A revolutionary approach

Helgason says that although the treatment currently applies to a relatively small group of melanoma patients, the breakthrough lies in the methodology itself: using each patient's tumor to design and manufacture a vaccine tailored specifically to that individual.

"It really is revolutionary," he says.

Helgason explains that all patients in the study received standard treatment with intravenous pembrolizumab for one year following surgery. One-third of the participants also received a placebo, while the others were given the experimental cancer vaccine intismeran alongside their standard treatment. The vaccine was administered by intramuscular injection every three weeks, for a total of nine doses.

"After approximately two years of follow-up, disease-free survival was 70% among those who received the placebo and 82.2% among those who received the cancer vaccine in addition to immunotherapy. This represents a 42% reduction in the risk of disease recurrence at the two-year mark and is considered a promising indicator of improved overall survival, although longer follow-up is needed to confirm this.

"Side effects from the vaccine were minimal or nonexistent, consisting mainly of flu-like symptoms lasting one to two days," Helgason says, adding that the vaccine is not yet available on the market.

However, he expects the American biotechnology company Moderna, which is developing the vaccine, to receive marketing authorization in the United States next year, followed by approval in Europe.

Moderna has already launched large-scale studies involving patients with various types of cancer, and Helgason believes the coming years will be particularly exciting.

内容来自 Mbl.is - News in English,版权归原作者所有。

阅读原文 ↗

把喜欢的内容,留在你的新标签页。

打开我的订阅